This study reveals the exact role of FSTL3 in immune evasion and ICB therapy resistance in CRC, which is essential for finding a new biomarker and therapeutic pathway for those CRC patients resistant to ICB therapy. The gene discussed is FSTL3; the disease is colorectal carcinoma.